Smartlab Europe

News

3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration to develop a new treatment to combat solid tumours

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organisation CDMO specialized in the process development and GMP manufacturing of biologics and Buzzard Pharmaceuticals, a Swedish pharmaceutical company developing and re-positioning drugs in oncology. Buzzard and 3P began their collaboration at...

Lonza and Ankyra Therapeutics Sign Agreement to Develop and Manufacture a Cytokine Fusion Protein

Ankyra Therapeutics, a biotechnology company developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response, and Lonza announced a collaboration to manufacture Ankyra’s cytokine-based immunotherapy for cancer patients. Lonza will provide cell line optimization and...

Lonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp and Portsmouth

Lonza announced significant investments to expand its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US). The expansion in Visp (CH) will see the development of a new large-scale mammalian drug substance manufacturing facility to expand capacity with...

Catalent Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Promethera Biosciences, the leader in advanced therapy development for severe liver diseases, announced that...

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the two organizations and their scientists will work to advance the understanding of immunology and inflammation through open scientific exchange. Additionally, Sanofi will provide...

Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the...

CytoDyn and AEIH to begin trials of leronlimab in severe Covid-19

This development is part of CytoDyn’s agreement to collaborate with AEIH to carry out the trials in up to 45 clinical sites in the country. These Phase III trials are anticipated to deliver the data required by the Brazilian regulatory...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »